We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+10.58%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$604M
AUM Growth
-$93M
(-13%)
Cap. Flow
-$139M
Cap. Flow
% of AUM
-22.99%
Top 10 Holdings %
Top 10 Hldgs %
48.64%
Holding
92
New
16
Increased
10
Reduced
22
Closed
33
Avg Time Held Equity + Options
3
quarters
Top 10 Avg Time Held Equity + Options
1.2
quarters
Top 20 Avg Time Held Equity + Options
1.4
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
1.2
quarters
Top 20 Avg Time Held Equity only
1.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Allogene Therapeutics
ALLO
|
+$29.3M |
| 2 |
Globus Medical
GMED
|
+$25.7M |
| 3 |
Cencora
COR
|
+$21M |
| 4 |
Cigna
CI
|
+$16.3M |
| 5 |
Viatris
VTRS
|
+$14.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$27.8M |
| 2 |
Corcept Therapeutics
CORT
|
+$27.2M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$27.1M |
| 4 |
LivaNova
LIVN
|
+$26.8M |
| 5 |
Embecta
EMBC
|
+$16.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.2% |
| 2 | Industrials | 6.36% |
| 3 | Miscellaneous | 3.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Hyperfine
HYPR
$92.4M
| – | – |
-1,000,000
| Closed | -$1.08M | – |
|
77
Integra LifeSciences
IART
$1.08B
| – | – |
-383,140
| Closed | -$3.61M | – |
|
78
Disc Medicine
IRON
$2.27B
| – | – |
-65,203
| Closed | -$4.17M | – |
|
79
Kymera Therapeutics
KYMR
$9.22B
| – | – |
-32,235
| Closed | -$2.68M | – |
|
|
80
LivaNova
LIVN
$4.21B
| – | – |
-421,615
| Closed | -$26.8M | – |
|
81
Monopar Therapeutics
MNPR
$504M
| – | – |
-173,506
| Closed | -$9.51M | – |
|
82
Nyxoah
NYXH
$133M
| – | – |
-50,839
| Closed | -$148K | – |
|
83
Organon & Co
OGN
$3.62B
| – | – |
-865,908
| Closed | -$5.19M | – |
|
84
PUT
Oscar Health
OSCR
$10.4B
| – | – |
-3,000
| Closed | -$34.4K | – |
|
85
ProQR Therapeutics
PRQR
$220M
| – | – |
-1,954,715
| Closed | -$3.17M | – |
|
86
QuidelOrtho
QDEL
$938M
| – | – |
-359,011
| Closed | -$5.9M | – |
|
87
Replimune Group
REPL
$1.18B
| – | – |
-720,036
| Closed | -$5.51M | – |
|
88
DELISTED
Simulations Plus
SLP
| – | – |
-200
| Closed | -$2.36K | – |
|
89
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-10,100
| Closed | -$532K | – |
|
90
Teleflex
TFX
$5.25B
| – | – |
-94,800
| Closed | -$11.3M | – |
|
91
Boundless Bio
BOLD
$58.2M
| – | – |
-163,679
| Closed | -$180K | – |
|
92
Shoulder Innovations Inc
SI
$376M
| – | – |
-210,641
| Closed | -$3.06M | – |
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Sio Capital Management held 92 positions worth $604M, down 13% from $697M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Sio Capital Management withdrew a net $139M in Q2 2026, closing 33 positions and reducing 22 holdings. Its most notable exit was Corcept Therapeutics, an estimated $27.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Industrials and Miscellaneous.
Against the trend, Sio Capital Management opened a new position in Allogene Therapeutics worth $27.7M.
- Sio Capital Management's largest Q2 2026 buy was Allogene Therapeutics: 13,323,431 shares worth $27.7M.
- Sio Capital Management added most to Cencora in Q2 2026, an estimated $21M increase.
- Sio Capital Management's biggest Q2 2026 reduction was Icon, cutting an estimated $27.8M.
- Sio Capital Management fully exited Corcept Therapeutics in Q2 2026, selling an estimated $27.2M.
- Sio Capital Management's ten largest holdings make up 49% of its $604M portfolio in Q2 2026.
- Sio Capital Management opened 16 new positions and closed 33 in Q2 2026.
- Sio Capital Management's portfolio value fell 13% quarter-over-quarter to $604M.
Based on Sio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.